Ref (type) | Population | Outcome, Interventions | Results and statistical analysis | Effect size | Favours |
Symptom severity | |||||
Systematic review |
730 people 2 RCTs in this analysis |
Mean difference in average Positive and Negative Syndrome Scale (PANSS) positive score at endpoint
with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported |
Mean difference –3.11 95% CI –4.30 to –1.93 |
Effect size not calculated | olanzapine |
Systematic review |
790 people 2 RCTs in this analysis |
Mean difference in average PANSS negative score at endpoint
with olanzapine (7.5–30 mg/day) with ziprasidone (40–160 mg/day) Absolute results not reported |
Mean difference –0.68 95% CI –3.81 to +2.45 |
Not significant | |
Systematic review |
529 people Data from 1 RCT |
Mean difference in average PANSS cognitive score at endpoint
with olanzapine (10–20 mg/day) with ziprasidone (80–160 mg/day) Absolute results not reported |
Mean difference –2.40 95% CI –3.63 to –1.17 |
Effect size not calculated | olanzapine |